NJ State Employees Deferred Compensation Plan Increases Stock Position in Teligent Inc (NASDAQ:TLGT)

NJ State Employees Deferred Compensation Plan increased its position in Teligent Inc (NASDAQ:TLGT) by 9.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 240,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. NJ State Employees Deferred Compensation Plan’s holdings in Teligent were worth $151,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Raymond James & Associates boosted its stake in shares of Teligent by 21.9% in the fourth quarter. Raymond James & Associates now owns 36,700 shares of the company’s stock valued at $50,000 after purchasing an additional 6,600 shares during the period. AMI Asset Management Corp boosted its stake in shares of Teligent by 0.5% in the first quarter. AMI Asset Management Corp now owns 2,727,695 shares of the company’s stock valued at $3,164,000 after purchasing an additional 13,403 shares during the period. Geode Capital Management LLC boosted its stake in shares of Teligent by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 479,485 shares of the company’s stock valued at $656,000 after purchasing an additional 17,951 shares during the period. Millennium Management LLC purchased a new position in shares of Teligent in the fourth quarter valued at $39,000. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Teligent by 27.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,729 shares of the company’s stock valued at $279,000 after purchasing an additional 43,414 shares during the period. Institutional investors and hedge funds own 66.59% of the company’s stock.

NASDAQ TLGT remained flat at $$0.68 during trading hours on Tuesday. 117,371 shares of the company’s stock were exchanged, compared to its average volume of 221,158. Teligent Inc has a 12-month low of $0.42 and a 12-month high of $4.52. The company has a debt-to-equity ratio of 14.43, a current ratio of 1.46 and a quick ratio of 0.79. The company has a market capitalization of $36.62 million, a PE ratio of -2.06 and a beta of 1.59. The company’s 50 day simple moving average is $0.66.

Teligent (NASDAQ:TLGT) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.04) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.04). Teligent had a negative net margin of 73.56% and a negative return on equity of 103.41%. The firm had revenue of $18.34 million for the quarter, compared to the consensus estimate of $17.58 million. On average, equities analysts predict that Teligent Inc will post -0.17 earnings per share for the current fiscal year.

Separately, ValuEngine downgraded shares of Teligent from a “buy” rating to a “hold” rating in a research note on Thursday, May 23rd.

About Teligent

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

See Also: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding TLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent Inc (NASDAQ:TLGT).

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.